REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
16/02/2026
Voltar para busca
Dado oficial do USPTO
PARVULET
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PARVULET
ST13
US500000088667306Classe
5, 10, 40, 42
Pedido
88667306
Registro
6269377
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
17/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 40, 42
Data de depósito
24/10/2019
Data de registro
16/02/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/02/2021
Última transação
17/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Philadelphia, PA
Examinador
MCDORMAN, ROGER THOMAS
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ADARE PHARMACEUTICALS, INC
ADARE PHARMACEUTICALS, INC
Representantes
Shawn Duckworth Dennemeyer & Associates, LLC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for the treatment of pain relief and pain managementfever managementshockhemorrhage and bleedingpre- and post-operative complications in the nature of hemorrhagebleedingthrombosisembolistrokeapoplexylesionsrespiratory and circulatory crises and dysfunctionscognitive dysfunctionsfibrosisinfectionsinflammationfever and sepsistraumas and emergenciesfracturesabrasionsburnspsychological and immunological shockpoisons and pollutionsanimal bites or stingsfeverrespiratory and cardiovascular shockcrises and dysfunctionshemorrhagebleedingthrombosisembolistrokeapoplexylesions and cognitive dysfunctionsphysical and psychological substance dependencedrug and alcohol dependencedrug tolerancewithdrawal symptomsconvulsionsAlzheimer diseasedementiasParkinson's diseaseinsufficient saliva and inability to swallowallergy/immunology disordersburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseases in the nature of fluAIDS/HIVanthraxplaguecholerabiological infectionsprion exposurediseases and afflictions of the gastroenterological systemdisbiosysdiseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesgenitourinary diseases and afflictionspremature laborpoison exposurecancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the earnose and throatdiseases and afflictions on the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictions; dietetic food adapted for medical use; diagnostic preparations for medical and veterinary use; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; synthetic peptides for pharmaceutical purposesfor the treatment of illnesses characterized by lack of such peptides and analogues thereof; vitamins; biologics being biopharmaceuticals and biologically active substances for the treatment of exocrine pancreatic insufficiencycystic fibrosis; pharmaceutical and nutraceuticals preparationsa drug delivery system comprising polymer-based oral tabletsoral powderoral liquidsoral suspensionsoral gelsoral emulsions for the immediate or controlledextendeddelayedpulsatilelocal release release of a wide variety of therapeutic agents within a certain time after ingestion; oral powder for reconstitutionnamely for immediate or controlledextendeddelayedpulsatilelocal release of a wide variety of therapeutic agents within a certain time after ingestion; medical gel; medicated candy; medicated chewing gum; medicated lollipops; sweets for medicinal purposessweets containing pharmaceutical and medical substances and compounds and nutraceuticals; drug delivery systems comprising polymer-based oral tabletsoral powder for immediate or controlledextendeddelayedpulsatilelocal release of a wide variety of therapeutic agents; drug delivery agents for various pharmaceuticalsdrugsmedicinescompounds and substances in the form of liquidsgelsgrainspowderemulsions; drug delivery powder for reconstitution in water before administration
Classe 10
Surgicalmedicaldental and veterinary apparatus and instrumentsdrug delivery apparatus and instruments in the form of containers in the nature of blister packs and sachets for various pharmaceuticalsdrugsmedicinescompounds and substances sold without medication; spoonscups and syringes for administering pharmaceutical substances and medicines; drug delivery systemsdrug delivery patches sold without medicationimplantable drug delivery portsintravenous bags sold empty for intravenous therapy
Classe 40
Treatment of materialsmillingmixinggrindingliquefyingpulverizingmelting and extrusion of medical and pharmaceutical substancescompounds and materials for others
Classe 42
Scientific research; technology consultation in the field of scientific research; design for others in the fields of pain relief and pain managementfever managementinflammationpharmaceutical drug and medicine developmentdevelopment of medicines and medicine goods and packaging in the fields of traumas and emergenciesaddictionsagingallergy/immunologyburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseasesdiseases and afflictions of the gastroenterological systemdisbiosys diseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesdiseases in the obstetrical- and gynecological fieldoccupational diseases and afflictionscancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the ear-nose and throatdiseases and afflictions on the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictionsveterinary preparations for the treatment of bovinesheephorsespigspoultryostrichrodentsdogscatscamelsdonkeyselephants; chemicalbiochemicalbiological and bacteriological research and analysis; pharmaceutical drug and medicine development services; design for others in the field of drugs and medicines; development of pharmaceutical preparations and medicines; professional consultancy pertaining to pharmacologybiotechnical and biomedical and medical and pharmaceutical substancespreparations and compounds; professional consultancy in the field of researchdesign and development of medicine and the dispensing of pharmaceutical preparations; pharmaceutical drug development services comprised of scientificindustrialtechnologicalbio technicalpharmaceuticalbiomedical and clinical research in the field of drugs and drug candidates and biologics; medical and scientific researchconducting clinical trials of new drug candidates; consultation in the field of scientific research pertaining to chemicalpharmaceutical and medical goods; design for others in the field of medical packaging and equipment; development of pharmaceutical preparations and medicines with improved compliance and acceptability by the patients; consultation in the field of biotechnological and biomedical scientific research; biochemical and molecular biological analyses; in vitro and in vivo preclinical tests and clinical tests of drug candidates and potential drugs; consultancy and research regarding pharmaceuticals in gel-likegelling and viscous liquid dosage forms; consultancy and research pertaining to pharmacology in the nature of alternative drugs for the youngelderly and those with difficulties swallowing solid dosage forms such as pills and tablets; development of in vitro and in vivo preclinical tests of drug candidates and potential drugs and biologics; biochemical and molecular biological analyses of pharmaceuticals and nutraceuticals preparations to ensure efficacy and safety; scientificindustrialtechnological and biotechnological analysis in the field of pharmaceutical and veterinary drug and medicine analysisanalysis of drug delivery apparatus and containersanalysis of synthetic peptides or other biologics analogues for pharmaceutical purposesanalysis of peptide substratesanalysis for the purpose of detecting various toxinsanalysis of drug candidates and potential drugs; preparation of materials for promotional documents and campaigns
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
20/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
20/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
16/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/12/2020
PUBO
PUBLISHED FOR OPPOSITION
01/12/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/11/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
26/10/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
23/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/10/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/07/2020
GNRT
NON-FINAL ACTION E-MAILED
23/07/2020
CNRT
NON-FINAL ACTION WRITTEN
23/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/07/2020
ALIE
ASSIGNED TO LIE
02/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/06/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/02/2020
GNRT
NON-FINAL ACTION E-MAILED
03/02/2020
CNRT
NON-FINAL ACTION WRITTEN
03/02/2020
DOCK
ASSIGNED TO EXAMINER
30/01/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/10/2019
NWAP
NEW APPLICATION ENTERED
28/10/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PARVULET ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.